The Drug Science Podcast

Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and Scientific Officer at Small Pharma Labs. Dr. Routledge takes us on a journey through her remarkable career path that ultimately led her to work at Small Pharma. With a wealth of experience in both preclinical and clinical settings, she has delved into psychiatric and neurological indications, honing her expertise in understanding and treating mental health disorders.

In this conversation, Dr. Carol Routledge draws upon her extensive clinical and psychedelic research background to shed light on the latest developments in DMT research and psychedelic integration therapy. With her profound insights, we explore the potential of these groundbreaking approaches to become formal medicines, revolutionizing the field of mental health treatment.

Tune in as Dr. Carol Routledge shares her passion for advancing mental health treatments through innovative research.





Nor adrenaline 

Small Pharma

Chris Timmermann - Human brain effects of DMT assessed via EEG-fMRI


British technology group (BTG)


Psychedelic experience

Alzheimers research uk 

★ Support this podcast ★

What is The Drug Science Podcast?

Professor David Nutt has spent a career making the argument for a rational, evidence-based approach to drug policy and drug use. The scientific evidence still challenges perceived wisdom on drugs and for that reason can appear to be contentious. In this podcast, the Professor explores the actual harms and potential benefits of various drugs, challenging myths surrounding classification and legislation, and exploring the societal impact of poorly informed drug policy. Using evidence in public policy should not be controversial. A podcast for anyone interested in understanding the scientific truth about drugs, free from political or moral concern.